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Objective To determine whether aneusomy for chromo- Results Eight of the 25 tumours examined (32%) showed
no evidence of chromosomal abnormalities as detectedsomes 7, 9 and 17 (reported to predict recurrence in
up to 65% of patients with superficial transitional cell by FISH for any chromosomes analysed. Twelve
tumours (48%) showed abnormalities for one or twobladder cancer and thus providing the opportunity for
early and eCective treatment) reflects specific genetic chromosomes, five tumours (20%) showed abnormali-
ties for multiple chromosomes and one tumour showedevents on these chromosomes or merely wider
unspecific genetic damage to the cell, e.g. that abnormalities for all chromosomes analysed, sugges-
tive of polyploidy.increased copy numbers for 7 and 17 reflect tumour
polyploidy. Conclusions Chromosomal abnormalities predictive of
recurrence occur largely in the absence of other grossMaterials and methods The study comprised 25 primary
tumours; 6 mm thick sections from formalin-fixed chromosomal lesions. In a small proportion of cases
other chromosomes are aCected, but this is almostand paraBn-embedded tumours were analysed.
Chromosome copy numbers were determined by fluo- always distinct from tumour polyploidy.
Keywords Bladder cancer, recurrence, molecular diag-rescence in situ hybridization (FISH) using pericen-
tromeric probes for chromosomes 7, 8, 9, 10, 11 and nosis, fluorescence in situ hybridization, chromosomes
9, 7, 17, polyploidy17. A minimum of 200 nuclei per tumour area were
scored by two independent observers.
frequency of recurrence and risk of progression makeIntroduction
frequent cystoscopic monitoring of patients a require-
ment of disease management [1,2].The diagnosis of bladder cancer relies heavily on direct
cystoscopic examination of the bladder which enables Recurrence rates can be reduced markedly by instil-
lation chemotherapy at initial diagnosis [3], but untilthe surgeon to biopsy and resect tumours [1,2]. Such
resection is curative for #20% of patients, but this recently no mechanism has been available to discrimi-
nate between patients at risk of recurrence and those forsuccess is limited to patients with noninvasive or only
locally invasive primary TCC (pTa/pT1). About one in whom such chemotherapy would be unwarranted. As a
result many urologists prefer to defer chemotherapy untilfive patients present with advanced disease (pT2–4) at
diagnosis [1,2]. Overall, 70% of patients presenting with recurrence is detected (Scottish Urological Oncology
Group, personal communications) to avoid over-treatingTCC are destined to have recurrence, the risk of which
is a function of time, although most patients will have patients who do not recur and exposing such patients
to the genotoxic aCects of chemotherapy without cause.recurrence within 2–4 years of diagnosis. Uniquely
amongst cancers, patients who experience one recur- Molecular markers which predict recurrence have
been detected by our previous research [4–6] and identifyrence almost inevitably return with further episodes of
recurrent disease such that the patient requires frequent patients most likely to benefit from regular cystoscopic
surveillance and/or instillation chemotherapy at primaryhospitalization to monitor disease recurrences [1,2].
Furthermore, a significant proportion of patients with diagnosis. Abnormalities of chromosomes 7, 9 and 17
have been shown to predict recurrence in up to 65% ofrecurrent disease will develop aggressive detrusor muscle
invasive tumours (10–20% of patients [1,2]). The high patients at primary diagnosis [7]. The challenge is to
expand these findings and increase the eBciency of such
tests before their acceptance into clinical diagnosticAccepted for publication 1 June 1999
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medicine. To achieve this goal it is first necessary to Luton, Beds, UK) for digoxigenin-labelled probes. This
protocol yielded easily quantifiable results of equal colourdetermine the nature of the genetic alterations detected.
The development and progression of tumours, includ- intensity for all probes.
The signals were visualized using an epifluorescenceing TCC, is driven by an accumulation of genetic
abnormalities [8–15]. Whilst chromosome-specific microscope (Leica, Milton Keynes, UK), with a 100-W
mercury arc lamp, and photomicrography performedabnormalities are frequently described, polyploidy is also
a frequent event in tumours and TCC is no exception using a Wild 48/52 photoautomat system (Leica, UK).
Regions for analysis by FISH were identified by examin-[12–14]. The evaluation of panels of two or three
chromosomal markers may fail to detect tumour poly- ing H&E-stained slides and areas to be scored marked on
an enlarged photocopy (200%) of the section. Signalsploidy and lead to a misunderstanding of the tumour
genetic profile. We have therefore expanded our previous for each chromosome in at least 200 discrete nuclei in
control and carcinoma sections were counted using astudies of chromosomes 7, 9 and 17 to determine
whether numerical aberrations occurred as a result of multichannel counter. The number of signals (0–8) were
recorded. One to three tumour areas were analysed, andor independently from tumour polyploidy. We have
further studied 25 of the 54 primary tumours from a proportion by three independent observers.
As a measure of overall chromosomal copy number,patients with TCC that either recurred (32) or did not
(22), described previously [4–7], a proportion of whom the mean chromosomal copy number (MCCN) was com-
puted as the total number of hybridization signals dividedalso progressed to detrusor muscle invasion (11).
Fluorescence in situ hybridization (FISH) data for chro- by the total number of nuclei. Monosomy was assessed
by criteria previously defined [4]. Normal ranges formosomes 7, 9 and 17 were available for all 54 tumours;
FISH analysis for chromosomes 8, 10 and 11 was MCCN and monosomy were defined as the mean ±3 sd.
Polysomy was defined as tumours with 10% of cellsperformed on the 25 primary tumours selected from
these groups and quantitative analysis of chromosome with 3 signals per nucleus [12–14]. The mean result
from all tumour areas (2–3 per tumour) was calculatedcopy number obtained.
to give an overall value for each tumour event.
Materials and methods
Results
The 25 primary tumours selected for this retrospective
study represent the spectrum of genetic alterations seen
FISH
in the previous study (monosomy chromosome 9, aneu-
somy chromosomes 7 and 17. and apparent normo- For chromosomes 7, 9 and 17, our previous reports
indicated that 24% of primary tumours (13 of 54)somy). The pathology for all tumours was reviewed
following the UICC 1978 guidelines [16]. showed loss of one copy of chromosome 9 [1]; 19% of
primary tumours (10 of 54) showed increased copyMorphologically normal disomic urinary bladder epi-
thelium served as a quality control for the FISH method. numbers for either chromosome 7 or 17 or both [5–7]
and one patient also had an increased copy number ofBoth normal tissues and tumours were accessed from
participating pathology laboratories (Departments of chromosome 9. Only 3.7% of primary tumours showed
simultaneous loss of chromosome 9 and gain of chromo-Pathology at Glasgow and Edinburgh Royal Infirmaries)
and serial sections of the formalin-fixed, paraBn wax- somes 7 and 17 [5–7]. Both monosomy of chromosome
9 (P=0.0016) and polysomy of 7 and 17 (P=0.0095)embedded tissues were cut onto silane-coated slides for
analysis. All tumours analysed had a representative were significantly associated with tumour recurrence,
being almost exclusively detected in primary tumourssection stained with haematoxylin and eosin (H&E),
and were re-staged and re-graded by one specialist from patients who exhibited recurrence as described
previously [4–7].pathologist (K.M.G.) following the UICC 1978 guide-
lines [16]. For chromosomes 8, 10 and 11, in 25 selected primary
tumours from our previous study, 32% (eight of 25)Dual-target FISH was performed with satellite repeat
sequence DNA probes for chromosomes 7, 8, 9, 10, 11 showed no abnormalities in any of the chromosomes
tested, either in this study or previously (chromosomesand 17, as described previously [4,5]. Hybridization was
visualized with fluorescein isothiocyanate (FITC) avidin, 7–11 and 17, data not shown). Nine of the remaining
17 primary tumours had one abnormality (Table 1). Ofbiotinylated anti-avidin and then the signal-amplified
with an additional FITC-avidin step (Vector Laboratories, these, five were monosomic for chromosome 9 whilst
normal for all other chromosomes evaluated, two wereBurlingame, CA) for biotinylated probes, and with sheep
antidioxigenin (Boehringer Mannheim, Lewes, East polysomic for chromosome 17 and two were newly
identified as polysomic for chromosome 8.Sussex, UK), FITC donkey antisheep (Stratech Scientific,
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Table 1 Mean chromosomal copy numbers
for aneusomic tumours in patients with
one or multiple chromosomes aCected,
shown in bold
Mean chromosomal copy numbers for chromosome
Stage/
grade 7 8 9 10 11 17
Single
pTaG1 1.68 1.7 0.83 1.54 1.68 1.67
pTaG1 1.61 1.71 1.03 1.62 1.7 1.67
pTaG2 1.56 1.71 1.05 1.72 1.68 1.64
pTaG2 1.67 1.69 1.85 1.76 1.74 2.12
pTaG2 1.61 2.54 1.60 1.65 1.71 1.64
pT1G2 1.84 1.58 0.87 nd nd 1.87
pT1G2 1.82 1.79 1.81 nd nd 2.13
pT1G3 1.74 1.6 1.18 1.68 1.74 1.8
pT2G3 1.76 2.64 1.37 nd nd 1.78
Multiple
pTaG1 1.61 2.05 0.84 1.73 nd 1.60
pTaG1 1.60 nd 0.87 0.86 1.67 1.53
pTaG1 2.33 2.34 1.11 1.60 2.28 2.44
pTaG2 1.66 1.71 0.91 1.57 1.72 2.16
pT1G2 1.98 2.48 1.66 1.35 1.85 2.01
pT1G3 2.79 3.31 2.25 2.37 2.5 2.71
pT1G3 2.71 2.54 1.68 2.07 2.31 2.54
pT1G3 2.21 2.44 1.59 nd 2.24 2.33
nd, not done.
Four tumours had abnormalities in two or three Of the G1 tumours, four showed no chromosomal
abnormalities, two showed monosomy 9 and threechromosomes; of these, three were monosomic for chro-
mosome 9 (Table 1). Additional lesions were polysomy showed multiple alterations (maximum five chromo-
somes). Of G2 tumours, three showed no chromosomal17, polysomy 8 or monosomy 10 (one case each). One
tumour showed polysomy for chromosomes 7, 8 and 17 abnormalities, four showed alterations aCecting single
chromosomes and two showed alterations involvingwith no alterations in chromosomes 9, 10 or 11
(Table 1), although the copy number for chromosome multiple chromosomes (up to 3). Of G3 tumours, one
showed no alterations, three showed aneusomy of one10 was at the low end of the normal range.
Only four cases had abnormalities in more than three chromosome and three showed aneusomy of multiple
chromosomes.chromosomes; of these, one was polysomic for all six
chromosomes tested (Table 1), suggesting a possible
polyploidy. Of the remaining tumours, two were normal Discussion
for chromosome 9 but polysomic for all other chromo-
somes tested, and one was polysomic for chromosomes In our recent studies we identified aneusomy of chromo-
somes 9, 7 and 17 as potential risk factors for recurrence7, 8, 11 and 17, monosomic for chromosome 9 and
normal for chromosome 10. in TCC of the urinary bladder [4–7]. Monosomy for
chromosome 9 or polysomy for chromosomes 7 and 17
were associated significantly with subsequent disease
Stage and grade
recurrence in a retrospective cohort analysis [4–7]. As
it is possible that these changes reflect wider geneticOf the 25 tumours analysed for all chromosomes, 15
were pTa, nine pT1 and one pT2, and nine were grade damage such as tumour polyploidy we extended the
studies to encompass chromosomes infrequently involved1, nine grade 2 and seven grade 3. Of the 15 pTa
tumours, six showed no chromosomal abnormalities, in genetic alterations in TCC (chromosomes 10 and 11)
and included analysis of chromosome 8. Abnormalitiesfive showed alterations of single chromosomes and four
showed multiple aneusomic events. Of the 10 pT1/2 in chromosomes 8, 10 and 11 are more frequently
associated with disease progression.tumours, two showed no abnormalities, three showed
alterations of single chromosomes (including the pT2 The results presented here suggest that: (i) monosomy
9 occurs independently other chromosomal abnormali-tumour) and five showed alterations of multiple
chromosomes. ties; (ii) polysomy of chromosomes 7 and 17 appears, in
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most cases, to occur in tandem, as in renal cell cancers [4–7]. However, neither lesion is significantly associated
with progression to higher tumour stage [4–7]. It would[17], but may also be associated with other chromosomal
changes; (iii) these lesions are rarely associated with appear that these events are linked with superficial or
locally invasive (pTa/pT1) tumour recurrence, thereforetumour polyploidy.
Monosomy 9 occurred independently of other lesions, we proposed that genes on these chromosomes are
specifically involved in the process of tumour recurrence,although in some tumours abnormalities of other chro-
mosomes were identified; half of the present tumours as distinct from tumour invasion [4–7].
In conclusion, following our recent studies identifyinginvestigated showed monosomy 9 alone. In the other
tumours, monosomy 9 was identified in the presence of genetic variables predictive of recurrence, the present
results exclude tumour polyploidy as the underlyingpolysomy 8, 7 or 7 and 17, and monosomy 10. No clear
pattern emerged to associate changes in chromosome 9 genetic event and show that aneusomy of chromosome
9 or chromosomes 7 and 17 are discrete genetic events.with other chromosome abnormalities. This finding sug-
gests that loss of chromosome 9 does not require other The linkage between these events and tumour recurrence
suggests that genes involved in tumour recurrence ingross chromosomal changes, nor does it necessarily drive
further gross chromosomal alterations. the absence of clinical progression are located on these
candidate chromosomes, as previously hypothesized.In >80% of cases both chromosomes 7 and 17 were
polysomic, to a similar degree as that reported previously
for renal cell cancers [17]. From the evidence presented Acknowledgements
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